IMPRINT Radiation Therapy for Thymic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The researchers are doing this study to find out whether hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) is a safe treatment that causes few or mild side effects in people with pleural metastases from thymic malignancies. The researchers will also look at whether hemithoracic IMPRINT is effective against participants' cancer.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, if you are on chronic oral steroid therapy for COPD, you may not be eligible to participate.
Is IMPRINT radiation therapy generally safe for humans?
How is IMPRINT treatment different from other treatments for thymic cancer?
What data supports the effectiveness of the treatment Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for thymic cancer?
Research shows that intensity-modulated pleural radiation therapy (IMPRINT) has been effective in treating malignant pleural mesothelioma, a type of cancer affecting the lining of the lungs, by improving tumor control and reducing side effects compared to older methods. This suggests that IMPRINT could potentially be effective for thymic cancer as well, given its success in similar conditions.12479
Who Is on the Research Team?
Charles Simone, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults aged 18-80 with thymic cancer that has spread to the lung and chest lining but not beyond. Participants must be in good physical condition, have a certain level of lung and kidney function, and cannot be pregnant or breastfeeding. They must agree to use contraception and have no history of severe lung disease, recent heart failure, or specific treatments like thoracic radiation.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants receive hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) over approximately 6 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment, including progression-free survival and radiation pneumonitis
What Are the Treatments Tested in This Trial?
Interventions
- Intensity-Modulated Pleural Radiation Therapy (IMPRINT)
Intensity-Modulated Pleural Radiation Therapy (IMPRINT) is already approved in United States, European Union, Japan for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor